FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D).C.	20549
---------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	urden
hours per response:	0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securiti or Section 30(h) of the Investment Con
	I

							34		hours	per response:		0.5				
Name and Address of Reporting Person* PATOU GARY			2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]					(Che	eck all appli	olicable)						
`	•	(Middle)	-	3. Date of Earliest Transaction (Month/Day/Year) 12/08/2021					Officer (give title Other (spe below) below)			cify				
			3	4. If Amendment, Date of Original Filed (Month/Day/Year)				Line) K Form	Form filed by One Reporting Person Form filed by More than One Reporting						
	Tab	le I - Nor	n-Deriva	ative S	ecurities Ac	quire	d, Dis	posed	of, c	r Ben	eficiall	y Owne	t			
1. Title of Security (Instr. 3)		Date	Execution Date,		Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			nd Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)	t of I ct Bei Ow	7. Nature of Indirect Beneficial Ownership				
						Cod	e V	Amount	:	(A) or (D)	Price	Transac	tion(s)		(ins	str. 4)
Shares			12/08/	2021		М		2,05	7	A	\$3.67(.67 ⁽¹⁾ 25,630 D		D		
Shares												12,500		I		e ote ⁽²⁾
	7											Owned				
			3A. Deemed 4. Execution Date, fi any (Month/Day/Year) 8)		5. Number	6. Date			_	itle and		8. Price of	9. Numbe	r of 10.		11. Natu
	nd Address of J GARY (F 50 GILMO:	ction 1(b). Ind Address of Reporting Person* J GARY (First) 50 GILMORE WAY BY A1 (State) Tab Security (Instr. 3)	ction 1(b). Ind Address of Reporting Person* J GARY (First) (Middle) 50 GILMORE WAY BY A1 V5G 4W8 (State) (Zip) Table I - Nor Security (Instr. 3) I Shares Table II -	ction 1(b). Filed Ind Address of Reporting Person* J GARY (First) (Middle) 50 GILMORE WAY BY A1 V5G 4W8 (State) (Zip) Table I - Non-Derivate (Month/Date (M	tion 1(b). Filed pursuan or Sec and Address of Reporting Person* J GARY (First) (Middle) 50 GILMORE WAY (State) (Zip) Table I - Non-Derivative Security (Instr. 3) Security (Instr. 3) Shares 12/08/2021 Shares Table II - Derivative Security Secu	ction 1(b). Filed pursuant to Section 16(a or Section 30(h) of the or Section	Table II - Derivative Securities Acquired, Filed pursuant to Section 16(a) of the or Section 30(h) of the Investm or Section 30(h) of the Investmant or Section 30(h) of the	Table I - Non-Derivative Securities Acquired, Disparse (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disparse (Month/Day/Year) Table I - Derivative Securities Acquired, Disparse (Month/Day/Year) Table II - Derivative Securities Acquired, Disparse (Month/Day/Year)	Filed pursuant to Section 16(a) of the Securities Excha or Section 30(h) of the Investment Company Ac Section 30(h) of the Investment S	Filed pursuant to Section 16(a) of the Securities Exchange A or Section 30(h) of the Investment Company Act of 1st and Address of Reporting Person* J GARY (First) (Middle) 50 GILMORE WAY (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, Code (Instr. 8) (Month/Day/Year) 2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE] 3. Date of Earliest Transaction (Month/Day/Year) 12/08/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) Filed pursuant to Section 16(a) of the Securities Exchange A or Section 30(h) of the Investment Company Act of 1st and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) Filed pursuant to Section 16(a) of the Securities Exchange Acquired Inc. Table II - Non-Derivative Securities Acquired, Disposed of, or Securities Acquired, Disposed of, or Table II - Derivative Securities Acquired, Disposed of, or Securities Acquired, Disposed of Securities Acquired, Di	rition 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE] 3. Date of Earliest Transaction (Month/Day/Year) 12/08/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial States 2. Transaction Date (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficial Shares Table II - Derivative Securities Acquired, Disposed of, or Beneficial Shares Table II - Derivative Securities Acquired, Disposed of, or Beneficial Shares Table II - Derivative Securities Acquired, Disposed of, or Beneficial Shares	rition 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE] 3. Date of Earliest Transaction (Month/Day/Year) 12/08/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficiall Execution Date, (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) Code V Amount (A) or Price (Shares) 1. Shares	Security (Instr. 3) Securities Securit	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 12/08/2021 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 1940 or Section 30(h) of the Investment Company Act of 1940 Xenon Pharmaceuticals Inc. [XENE] S. Relationship of Reporting (Check all applicable) X Director Officer (give title below) 4. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 1. Shares 12/08/2021 M 2, Ose W Amount (A) or Price (Instr. 3 and 4) 12,500 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the investment Company Act of 1940 I GARY 2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE] 3. Date of Earliest Transaction (Month/Day/Year) (First) (Middle) 50 GILMORE WAY A. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Security (Instr. 3) A. Securities Acquired (A) or Date (Instr. 3) (Shares 12/08/2021	Security (Instr. 3) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Explanation of Responses:

\$3.67⁽¹⁾

1. The exercise price was converted from \$3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Date Exercisable

(3)

Expiration Date

12/31/2021

Title

Commor

Shares

2. By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

12/08/2021

3. 1/3 of the shares subject to the Option vested on January 1, 2013 (the "2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the 2012 Vesting Commencement Date over the following 2 years.

Remarks:

Stock Option

(Right to

/s/ Cassandra Robinson, 12/10/2021 Attorney-in-fact

0

D

** Signature of Reporting Person Date

Amount or Number

of Shares

2,057

\$0.00

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

M

(A) (D)

2,057

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.